Our strategy at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to take advantage of discoveries in basic cancer biology, in conjunction with clinical research to: (1) develop and apply innovative therapeutic and preventive strategies to cancer patients;(2) describe the molecular mechanisms involving specific clinical phenotypes and behaviors;and (3) apply discoveries and strategies to the Maryland community, with the specific focus on cancer disparities. In this application, UMGCC seeks its first competitive renewal of the successful Cancer Center Support Grant (CCSG) application that was awarded in August 2008, in the present application, UMGCC is represented by 215 members working in five full and one developing research programs with 10 full and 3 developing shared services. UMGCC provides an effective umbrella supporting the multidisciplinary cancer research activities of this talented group of investigators. Total cancer funding rose from $47.1 million in 2007 to $62.0 million in 2009. NCI funding in that time increased from $14.4 million to $25.7 million. Supplements will push total cancer funding above $80 million in 2010. In FY2009, UMGCC served almost 2,300 new cancer patients and handled 43,547 outpatient visits, 32,405 infusion visits, and 1,327 inpatient admissions. During FY2009, 1,198 patients participated in over 200 clinical trials. Remarkably, 33 percent of clinical trial participants in FY2009 were underrepresented minorities, reflecting UMGCC's unique position and mission to involve the minority community in state-of-the-art clinical/translational research. UMGCC researchers have made outstanding contributions to our understanding of cancer biology, and important recent work from our laboratories and clinics is now the standard of care worldwide. A 2010 nationwide ranking of U.S. cancer programs placed UMGCC 21st out of more than 900 cancer programs and 18th among NCI-designated centers. Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research.

Public Health Relevance

The mission of the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to undertake innovative basic and clinical research that will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA134274-04
Application #
8179933
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2008-08-08
Project End
2016-07-31
Budget Start
2011-08-24
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$1,565,163
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wang, Lei; Ma, Xiao; Xu, Xiaolei et al. (2017) Systematic identification and characterization of cardiac long intergenic noncoding RNAs in zebrafish. Sci Rep 7:1250
Nowak, Rebecca G; Ambulos, Nicholas P; Schumaker, Lisa M et al. (2017) Genotyping of high-risk anal human papillomavirus (HPV): ion torrent-next generation sequencing vs. linear array. Virol J 14:112
Thomas, Stefani N; Yang, Austin J (2017) Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain. Methods Mol Biol 1523:161-177
Kaczanowska, Sabina; Joseph, Ann Mary; Guo, Jitao et al. (2017) A Synthetic CD8?:MyD88 Coreceptor Enhances CD8+ T-cell Responses to Weakly Immunogenic and Lowly Expressed Tumor Antigens. Cancer Res 77:7049-7058
Larrosa-Garcia, Maria; Baer, Maria R (2017) FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions. Mol Cancer Ther 16:991-1001
Stick, Line B; Yu, Jen; Maraldo, Maja V et al. (2017) Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys 97:754-761
Connolly, Nina P; Stokum, Jesse A; Schneider, Craig S et al. (2017) Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. PLoS One 12:e0174557
Carter-Cooper, Brandon A; Fletcher, Steven; Ferraris, Dana et al. (2017) Synthesis, characterization and antineoplastic activity of bis-aziridinyl dimeric naphthoquinone - A novel class of compounds with potent activity against acute myeloid leukemia cells. Bioorg Med Chem Lett 27:6-10
Young, Christina A; Rorke, Ellen A; Adhikary, Gautam et al. (2017) Loss of epidermal AP1 transcription factor function reduces filaggrin level, alters chemokine expression and produces an ichthyosis-related phenotype. Cell Death Dis 8:e2840
Nowak, Rebecca G; Bentzen, Søren M; Ravel, Jacques et al. (2017) Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. AIDS 31:857-862

Showing the most recent 10 out of 239 publications